Investopedia: Waiting For A Clearance Sale On Ulta

As investors in retailers like Talbots (NYSE:TLB) or American Eagle (NYSE:AEO) can easily attest, this is not the easiest environment for retail. Oh true, conditions are better now than a year or two ago, but retailers really need to offer something distinctive in terms of product selection, pricing or shopping experience to draw in the crowds.

To that end, Ulta (Nasdaq:ULTA) seems to have hit on an attractive and differentiated concept - a beauty and personal care superstore format that is competitive on pricing while offering a wide selection and pleasant environment. Like lululemon (Nasdaq:LULU) and its own differentiated products and branding, Ulta is carving out an impressive growth trajectory while many of its rivals are struggling to hold on to what they have.



Keeping up the Momentum in Q1
Ulta's fiscal first quarter showed no slowdown in the company's momentum. Sales were up almost 21% on a reported basis, with same-store sales up more than 11%. There is a decided lack of direct comps to Ulta (one of the positives in the company's thesis), but anecdotal from the likes of Macy's (NYSE:M), Nordstrom (NYSE:JWN) and Kohl's (NYSE:KSS) would suggest that Ulta's performance is quite a bit stronger than the average department store cosmetics counter.


To read the full piece, please follow the link:
http://stocks.investopedia.com/stock-analysis/2011/Waiting-For-A-Clearance-Sale-On-Ulta-ULTA-LULU-M-JWN-WAG-AVP-SBH0608.aspx

Cardinal Puts Some Cash To Work

Large piles of cash seem to tempt people into making bad decisions. At the corporate level, large cash balances often attract so-called "activist investors" looking for quick paydays or to embolden management into ill-timed buybacks or illogical acquisitions. That does not seem to be a problem with Cardinal Health (NYSE:CAH), though, as this large medical distributor has used almost $2 billion of its cash on hand to make a pair of acquisitions that seem to make a lot of sense. 

Kinray and Independent Pharmacies
Almost two weeks ago, Cardinal announced the acquisition of privately-held Kinray Inc for $1.3 billion in cash. A pharmaceutical distributor focused mostly on New York City and the Northeast U.S., Kinray will enhance Cardinal's exposure to independent pharmacies. While major chain pharmacies like Walgreen (NYSE:WAG) and CVS Caremark (NYSE: CVS) are a huge part of Cardinal's revenue base, the company makes a lot more money (on a margin basis) serving smaller customers, so expanding that customer base should be pretty accretive for Cardinal.

Buying Further into China ...
On Monday, Cardinal announced its latest deal - paying $470 million in cash (and assuming $60 million in debt) to acquire Zuellig Pharma China. Part of Zuellig Pharma (which in turn is part of the even larger Zuellig Group), Zuelling Pharma China is one of the largest distributors of pharmaceuticals and medical devices and supplies in China. Serving over 123,000 independent pharmacies and 49,000 provider locations, this Zuellig buy certainly enhances Cardinal's scale in what is almost sure to be a major market for medical distribution for some time to come. (For more, see Top Factors That Drive Investment In China.)

Please follow the link for the full story:
http://stocks.investopedia.com/stock-analysis/2010/Cardinal-Puts-Some-Cash-To-Work-CAH-WAG-CVS-ABC-MCK-OMI1130.aspx